title: Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing.
abstract: OBJECTIVE
  To examine the difference in improvement of lower urinary tract symptoms between morning and evening dosing of α1 -blocker naftopidil.
  
  
  METHODS
  A total of 177 male patients with nocturia were included in the present study and randomized to morning or evening dosing of naftopidil. The International Prostate Symptom Score, quality of life index and nocturia quality of life index were compared between the two study groups at 12 weeks.
  
  
  RESULTS
  A total of 143 patients (morning group: n = 70, evening group: n = 73) were analyzed as a result of the dropout of 34 patients because of failure to give consent, adverse events and failure to attend. Nocturia, quality of life index and nocturia quality of life index at 12 weeks were significantly better in the evening group compared with the morning group. In a multivariate model, both the dosing time of naftopidil and the initial nocturia quality of life index were significantly associated with change in nocturia quality of life index.
  
  
  CONCLUSIONS
  Evening dosing of naftopidil seems to be more effective in treating nocturia in male patients with lower urinary tract symptoms.
authors.affiliation: Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan.
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kuratsukuri
authors.forename: Rikio
authors.initials: R
authors.lastname: Yoshimura
authors.forename: Takahisa
authors.initials: T
authors.lastname: Adachi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Ohmachi
authors.forename: Shinji
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nakamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tamada
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakatani
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009281:Naphthalenes / Q000008:administration & dosage*; D053158:Nocturia / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000150:complications*; D011788:Quality of Life; D013997:Time Factors; D016896:Treatment Outcome; D014563:Urodynamics
chemical_list: D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil
keywords: administration time; male lower urinary tract symptoms; naftopidil; nocturia